{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Here is the number of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence.","groups":[{"description":"1x10\\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.\n\nE7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\\^11 cells) will be administered intravenously over 20 to 30 minutes.","id":"OG000","title":"Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 8 months and 6 days.","title":"Number of Participants With Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}